Dianthus therapeutics announces initiation of phase 2 magic trial of dnth103 in generalized myasthenia gravis (gmg)

Top-line results from gmg magic trial anticipated in 2h 2025 building a neuromuscular franchise with dnth103 through additional planned phase 2 trials in multifocal motor neuropathy (mmn) and chronic inflammatory demyelinating polyneuropathy (cidp) dnth103 is a potential best-in-class, potent classical pathway inhibitor planned for self-administration as a low volume, subcutaneous injection once every two weeks new york and waltham, mass., feb. 26, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the initiation of the phase 2 magic trial of dnth103 in patients with generalized myasthenia gravis.
DNTH Ratings Summary
DNTH Quant Ranking